2013 Fiscal Year Final Research Report
AbEx: a novel drug carrier based on human antibody-displaying exosome
| Project/Area Number |
24790542
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Applied pharmacology
|
|---|
| Research Institution | Fukuoka University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2012-04-01 – 2014-03-31
|
| Keywords | ドラッグデリバリー / エクソソーム / 抗体 |
|---|
| Research Abstract |
This study aims to develop a novel DDS utilizing a human antibody-displaying esoxome (AbEx) loaded with exogenous drugs. Because exosomes are able to be prepared from self-derived cells, if antibody to be displayed is produced with fully human V-genes, it is highly unlikely that the AbEx induces a host immune response. Moreover, tumor-specific and effective accumulation of the AbEx is expected to be accomplished by the antibody-directed tumor targeting and the enhanced permeation and retention effect.
We successfully constructed a chimeric gene to produce AbEx which displays fusion proteins of a single-chain variable fragment of human anti-carcinoembryonic antigen (CEA) antibody and CD63 on the membrane. It was found that the AbEx actually binds to CEA-expressing cancer cells and is internalized into the cytosol. Unfortunately, the binding specificity was relatively low, we are optimizing the molecular design and expression system for obtaining more functional AbEx.
|
